Phase I/II study of docetaxel and OSI-774 (erlotinib) in solid tumor patients with an emphasis on NSCLC [non-small cell lung cancer] using molecular correlates as potential markers of response.

Trial Profile

Phase I/II study of docetaxel and OSI-774 (erlotinib) in solid tumor patients with an emphasis on NSCLC [non-small cell lung cancer] using molecular correlates as potential markers of response.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Docetaxel (Primary) ; Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Mar 2012 Companies (Genentech, Aventis Pharmaceuticals) added as trial sponsor as reported by ClinicalTrials.gov.
    • 06 Apr 2010 Additional lead trial centre (National Cancer Institute) and lead trial investigator (Gandara DR) added as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top